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median (range) ANC and ALC at the time of RSV diagnosis was
1.6 (0 - 11) and 0.8 (0 - 7.3), respectively. Among the 35 pa-
tients with URTI, 12 received IR while 23 did not. None of the
12 patients treatedwith IR progressed to LRTI. In contrast, 6 of
the 23 untreated patients (24%) with URTI progressed to LRTI.
Of the 31 patients with LRTI (25 initially diagnosed with LRTI
and 6 patients who progressed from URTI to LRTI), there were
four deaths occurring within 60 days of RSV diagnosis (two
deaths directly from RSV, one from disease relapse, and one
from GVHD). In patients with LRTI (25 patients with LRTI at
diagnosis plus 6 patients who progressed from URTI to LRTI),
RSV-related mortality was (6.4%). On univariate analysis, only
the presence of GVHD signiﬁcantly predicted the develop-
ment of LRTI in patients with URTI (P ¼ .028); however, the
use of inhaled ribavirin had a protective effect that was
marginally signiﬁcant (P¼ .074). Early use of IR in high-risk
transplant and leukemia patients can both reduce the pro-
gression fromURTI to LRTI and improve the historically dismal
outcomes of patients with RSV pneumonia.297
Physical Therapy during the Hemopoietic Stem Cell
Transplant Process to Improve Quality of Life
Andrea Jana Gevedon, Jessica King Monfreda. Physical therapy,
occupational therapy, and recreational therapy., Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH
Clinical Question (in PICO format)
Background / Purpose of BESt Development
Hemopoietic stem cell transplant can have profound and
lasting adverse effects on an individual’s physical and psy-
chological well-being (Wolin 2010 [1a], Tsimicalis 2005 [1a],
Baumann 2011 [2b], Jarden 2009 [2b]). The HSCT treatment
results in a decline in physical function functioning related to
loss of muscle mass and muscle strength andmuscle atrophy
is associated with several transplant related problems,
including immunosuppressive therapy, bed rest, and drug
toxicities (Wolin 2010 [1a], Knols 2005 [1a], Wiskemann 2008
[1b], Baumann 2011 [2b]). The experience of the isolated
environment and the stress of a life threatening illness,
resulting in fatigue, anxiety, depression, and fear, may also
contribute to negative effects on physical function and QoL
(Tsimicalis 2005 [1a]).
Chemotherapy results in anemia, which can affect cardiore-
spiratory ﬁtness and cause skeletal muscle atrophy and
weakness. Chemotherapy toxicities can impede adequate
nutrition needed to maintain muscle mass. Radiation therapy
can lead to lung ﬁbrosis, resulting in decreased pulmonary
function. Cranial radiation in childhood has been strongly
linked to physical inactivity during adulthood (Wolin 2010
[1a]). Individuals being treated for pediatric cancers, in
particular, tend to experience adverse effects of treatment
including impaired growth, decreased neurological and/or
cardiac function, endocrine complications, osteoporosis and
obesity (Wolin 2010 [1a]). All of these side effects can lead to a
decline in physical functioning and contribute to experiences
of fatigue, anxiety, and depression (Wolin 2010 [1a]).P: Among school aged children and adolescents receiving
hemopoietic stem cell transplant (HSCT)
I: does physical therapy (PT) intervention (active participation
in mobility, endurance, strength exercise)
C: compared to no intervention
O: improve the patient’s quality of life (QoL)?In addition to the symptoms and side effects, the treatment
requires prolonged isolation, which can also impede func-
tional activity and impair psychological well-being (Trem-
olada 2009 [1b]). Activity restrictions and limited exercise
options hinder the individual’s ability to sustain physical
function throughout this process. Mentally, the challenges
pediatric patients experience while undergoing HSCT may
have a long lasting impact on QoL (Tremolada 2009 [1b]).
Because survival rates have increased, the need to address
these quality of life issues and the impact of functional
impairment has grown signiﬁcantly. It is important to
consider not only immediate survival, but also long term
recovery of this patient population. The purpose of devel-
oping this BESt was to identify interventions that can
improve function and positively impact outcomes improving
HSCT pediatric patients’ QoL.298
Nephrotoxicity of Co-Administration of Tacrolimus and
Teicoplanin in Allogeneic Hematopoietic Stem Cell
Transplant Recipients
Takehiko Mori, Takayuki Shimizu, Jun Kato, Sumiko Kohashi,
Yuya Koda, Masuho Saburi, Shinichiro Okamoto. Division of
Hematology, Keio University School of Medicine, Tokyo, Japan
Backgrounds: Both tacrolimus and glycopeptide antibiotics
are nephrotoxic, and are frequently co-administered after
hematopoietic stem cell transplantation (HSCT). The aim of
this study is to evaluate the nephrotoxicity of co-adminis-
tration of tacrolimus and glycopeptide antibiotic, teicoplanin,
in HSCT recipients.
Patients and Methods: Sixty-seven patients who received
intravenous tacrolimus and teicoplanin concomitantly for
more than four days after allogeneic HSCT were retrospec-
tively examined. Therapeutic drug monitoring (TDM) was
performed in all patients both for tacrolimus and teicoplanin.
Results: The median duration of the co-administration of
tacrolimus and teicoplanin was 11 days (range: 4-40). The
mean serum creatinine (sCr) level tended to be elevated after
the co-administration of tacrolimus and teicoplanin (from
0.690.26 to 0.750.30 mg/dL; P¼ 0.08); however, a two-
fold or greater increase of sCr was observed only in 2 (3.0%)
patients. Increased sCr was tolerable and reversible.
Conclusion: These results suggest that the nephrotoxicity of
the co-administration of tacrolimus and teicoplanin is min-
imal after allogeneic HSCT if the TDM of each drug is properly
applied.299
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Japanese encephalitis (JE) virus is one of the most wide-
spread causes of viral encephalitis in Asia and western pa-
ciﬁc. JE causes long-term neurological morbidities and
mortality. National implementation of JE vaccine effectively
reduces incidences of JE in Asian countries. A live-attenuated
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S199JE vaccine (SA 14-14-2) has lesser local reaction and milder
systemic side effects compared to inactivated JE vaccine.
Since antibody (Ab) titers to vaccine-preventable diseases
decline after hematopoietic stem cell transplantation (HSCT),
therefore reimmunization recommendations have been
developed for post HSCT survivors. However, there has been
no recommendation for revaccination of JE vaccine in post
HSCT recipients. This study aimed to measure the immuno-
genic response to the live-attenuated JE vaccine (SA 14-14-2)
in post HSCT recipients. We enrolled patients who under-
went allogeneic HSCT at least 2 years, discontinued immu-
nosuppressive agents at least 6 months, and had no evidence
of chronic GVHD. The live-attenuated JE vaccine (SA 14-14-2)
was administered to the patients. JE neutralizing Ab titers
were measured before JE vaccination, then at 1st, 3rd, 6th, and
12th months after vaccination by a plaque reduction
neutralizing test. Patients with Ab titer less than 10 at 3rd
month received a second injection at 6th month. Then, the JE
titers were tested at 7th, 9th, 12th, and 18th months. Side ef-
fects of the JE vaccine were recorded by vaccine card sup-
plied to parents or guardians. A total of 28 patients (M:F ¼
11:17) with a median age of 13 years (4-21 years) partici-
pated in the study. The median time from HSCT was 4.13
years (2.1-9.8 years). The underlying diseases were thalas-
semia (50%) and hematologic malignancies (50%). Ten pa-
tients (36%) had Ab in the preventive range before
vaccination (group 1). Nine of 18 patients (50%) sero-
converted at 3rd month after single JE vaccination (group 2)
but only 3 of them had sustained protective Ab levels at 12th
month. Nine patients remained absence of JE Ab after the 1st
injection (group 3). Seven of these 9 patients (78%) sero-
converted at 3rd month after 2nd JE vaccine injection which
all of them could sustain the protective Ab levels at 12th
month. There was no difference of lymphocyte subset (CD4,
8, 16/56, and 19) between these 3 groups. There was no
incidence of systemic reaction reported in this cohort. In
conclusion, post HSCT survivors had low seroconversion rate
after single dose of the live-attenuated JE vaccine (SA 14-14-
2). Post HSCT survivors living in or traveling to the JE
endemic countries may require at least 2 doses of the JE
vaccine to ensure the protective Ab level.300
A Multi-Disciplinary Approach to Identiﬁcation and
Treatment of Hyperglycemia on an Inpatient
Hematopoietic Stem Cell Transplant (HSCT) Unit
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Background/Problem: The incidence of hyperglycemia
during and after HSCT has been shown to increase length of
stay as well as the risk of neutropenic infections during
transplantation. Severe hyperglycemia has been shown to
predict the incidence acute graft-versus-host disease. There
is a paucity of literature regarding implementation of a sys-
tematic screening and intervention program within HSCT
programs to proactively address hyperglycemic events and
minimize the potential effects of untreated hyperglycemia.
Intervention: A multi-disciplinary “Hyperglycemia Team”
reviewed the literature and implemented a comprehensive
screening and intervention program. A hyperglycemic proto-
col was implemented on the HSCT units in 2012. All patients
with at least one serum or capillary blood glucose (BG) greaterthan 200 mg/dL in the previous 24 hour period were identi-
ﬁed via computer-generated reports eachmorning. A Certiﬁed
Diabetes Educator (CDE) then screened each patient’s medical
record to assess whether the patient was receiving insulin
therapy to treat hyperglycemia. If the patient was not
receiving insulin therapy or the therapy was inadequate, the
CDE would contact the primary HSCT providers to facilitate
implementation or escalation of a hyperglycemic protocol
and/or an endocrinology team consultation.
Results: All serum and capillary blood glucoses performed
on the inpatient stem cell transplant units were analyzed for
12 months prior to (n¼14780) and subsequent to (n¼15138)
our intervention. The incidence of BG levels > 180 mg/dL
signiﬁcantly decreased by 16% (p¼<.0001) while the inci-
dence of hypoglycemic events (BG levels < 60 mg/dL)
requiring medical intervention signiﬁcantly decreased by
42% (p¼<.0001) (Figure A). The number of blood glucose
levels at the target goal of 100-180 mg/dL signiﬁcantly
increased by 7.8% (p¼<.0001).
Conclusion: A multi-disciplinary approach to the identiﬁ-
cation and treatment of hyperglycemia is essential to
decrease the incidence of hyperglycemia. We concurrently
achieved a signiﬁcant decrease in BG levels and the incidence
of hypoglycemic events requiring medical intervention.
Serum/Capillary Blood Glucose Levels on HSCT Units-
Figure A301
The Effect of Communication Skills Training on Nurses’
Conﬁdence and Competence in Providing Psychosocial
Support to Patients and Families
Sharon Penko. Cancer and Blood Diseases Institute, Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH
Background:Many bone marrow transplant (BMT) patients
and families report clinically signiﬁcant levels of psycho-
logical distress prior to the start of treatment and afterward.
Nurses generally feel conﬁdent in providing care for the
physical needs of patients, but often ﬁnd it more difﬁcult to
address patients’ emotional concerns and report a lack of
skill in this area. Supportive and patient-centered commu-
nication is an important part of nursing practice, especially
with patients who are experiencing emotional and psy-
chological distress, and disruption to social, occupational,
and physical lifestyle. To address this issue, the clinical
question, “Among direct care nurses, does communication
skills training compared to no communication skills
training, affect nurses’ conﬁdence and competence in
providing psychosocial support to patients and families?”
was developed. The ACE Star Model of Evidence-Based
Practice Change: Knowledge Transformation (Stevens,
2012) was used for this project. A literature search was
conducted. Eight articles were critically appraised and a
moderate grade was assigned. Communication skills
training has been shown to be effective at increasing nurses’
ability to provide psychosocial support to patients, conﬁ-
dence in providing psychosocial support, conﬁdence in
handling conﬂicts and criticism, competency in communi-
cating, and communication-related self-efﬁcacy. Nurses
also attended to the psychological and social needs of pa-
tients more effectively and reported that the skills trans-
lated well into the workplace.
Implementation: Communication skills training will be
added to the Therapeutic Collaborative training for BMT
nurses in the spring of 2014. This training aims to assist
nurses in forming therapeutic relationships with their pa-
tients and families, addressing professional boundaries, the
